Kennedy Capital Management LLC Acquires 28,929 Shares of Immunome, Inc. $IMNM

Kennedy Capital Management LLC boosted its holdings in Immunome, Inc. (NASDAQ:IMNM) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 286,355 shares of the company’s stock after buying an additional 28,929 shares during the quarter. Kennedy Capital Management LLC owned approximately 0.26% of Immunome worth $6,151,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in IMNM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Immunome by 44.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock valued at $316,000 after buying an additional 14,398 shares during the last quarter. Creative Planning bought a new position in Immunome during the 2nd quarter worth approximately $167,000. Rhumbline Advisers raised its holdings in Immunome by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock worth $1,008,000 after purchasing an additional 19,526 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Immunome by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock worth $2,612,000 after purchasing an additional 9,686 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in Immunome during the 2nd quarter worth approximately $1,021,000. Institutional investors own 44.58% of the company’s stock.

Insider Activity at Immunome

In other news, CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00. Following the completion of the sale, the chief financial officer owned 54,037 shares in the company, valued at $1,184,491.04. The trade was a 54.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 9,438 shares of Immunome stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares of the company’s stock, valued at $476,080. This represents a 30.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 139,438 shares of company stock worth $2,964,664. 7.21% of the stock is owned by insiders.

Immunome Stock Down 1.7%

NASDAQ:IMNM opened at $18.07 on Tuesday. The company has a fifty day moving average of $21.70 and a 200-day moving average of $21.71. The firm has a market capitalization of $2.05 billion, a P/E ratio of -7.59 and a beta of 2.04. Immunome, Inc. has a twelve month low of $7.96 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on IMNM shares. Craig Hallum raised their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Wedbush restated an “outperform” rating and set a $31.00 price target on shares of Immunome in a report on Friday. Stephens lowered their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Finally, Barclays started coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target for the company. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Immunome currently has an average rating of “Moderate Buy” and an average price target of $33.17.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.